Neem's Hill (NEEMS) Q3 2026 earnings summary

Executive summary

• Q3 net sales were 3,376 KSEK vs 3,324 KSEK YoY; 9M sales were 9,466 KSEK vs 9,637 KSEK, all from Animal Care.

• Q3 net loss was 1,291 KSEK vs 1,267 KSEK; 9M net loss was 5,486 KSEK vs 5,532 KSEK.

• Treatment-kit sales continued to grow as installed vetlQure systems were used more frequently; more than 60 systems were installed globally and over 4,500 Animal Care treatments sold since launch.

Financial highlights

• Q3 operating loss was 1,097 KSEK vs 1,065 KSEK; 9M operating loss was 4,460 KSEK vs 4,322 KSEK.

• Q3 external costs rose to 4,116 KSEK from 3,207 KSEK, reflecting sales and marketing capacity added since June, seasonal conferences, and one-off consultant and financial/legal advisory costs.

• Q3 operating cash outflow was 2,470 KSEK vs 1,663 KSEK; 9M operating cash outflow was 5,393 KSEK vs 3,406 KSEK.

Outlook and guidance

• Priorities are converting expanded commercial reach into new installations and helping more clinics establish regular treatment activity; positive cash flow remains a key objective.

• Human Care development in India may advance through selected clinical projects, subject to available funding, clinical partnerships, and an agreed plan.

• North American technical services, logistics, and administration may be strengthened, with any expansion paced to available funding.